The USPSTF recommends colorectal cancer (CRC) screening starting at age 50 years and continuing through age 75 years.
Salix announced the availability of Xifaxan 550 in a new two-week treatment Pack. The Xifaxan two-week Pack contains 42 tablets, providing a full course of treatment for irritable bowel syndrome with diarrhea (IBS-D).
Targeting the bacteria Helicobacter pylori with a short course of combination therapy may help decrease the risk of gastric cancer.
In a new study, some patients with advanced ulcerative colitis (UC) had better outcomes with elective colectomy compared to immunosuppressant therapy, even though this is typically a treatment of last resort.
The Food and Drug Administration (FDA) announced that Emend (aprepitant; Merck) is currently in shortage.
Use of proton pump inhibitors (PPIs) increase the risk of an adult experiencing a heart attack by 16-21% compared to those who don't use commonly prescribed antacids, a large study has found.
The FDA has approved Viberzi (eluxadoline; Actavis) and Xifaxan 550mg (rifaximin; Salix) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
A non-aggressive Clostridium difficile strain significantly reduced the risk of Clostridium difficile infection (CDI) recurrence in a small study published in the Journal of the American Medical Association.